PpProf. Peptide
← Back to Supplement Library

Resveratrol

Longevity

Last reviewed: May 26, 2026

Also Known As: Trans-resveratrol, RSV, stilbenoid, Polygonum cuspidatum (Japanese knotweed source), “French Paradox” compound

Supplement Class: Polyphenol stilbenoid / SIRT1 activator (direct + indirect via AMPK) / NF-κB inhibitor / caloric restriction mimetic

Evidence Tier: Mixed (key honesty deviation from typical marketing) — Strong mechanism (SIRT1, AMPK, NF-κB, caloric-restriction mimicry); Moderate biomarker effects (Liu 2015 BP meta-analysis, Hausenblas 2015 T2D meta-analysis, Brasnyó 2011 insulin sensitivity); Strong preclinical animal evidence (Baur 2006 Nature paper on high-calorie-diet mice); Limited/Null hard clinical endpoints in elderly (DO-HEALTH 2020 era); bioavailability constraint is the central practical challenge

What is resveratrol?

Resveratrol is a polyphenol stilbenoid found in red grape skins, blueberries, peanuts, and most famously red wine — sparking the “French Paradox” epidemiological interest in 1990s cardiovascular research. David Sinclair's laboratory identified resveratrol as a sirtuin-activating compound (STAC) in 2003, triggering the modern wave of longevity research. The mechanism case is mature — SIRT1 activation (directly or indirectly via PDE inhibition + AMPK), caloric-restriction mimicry, NF-κB inhibition, antioxidant effects. The biomarker evidence is moderate — Liu 2015 meta-analysis documents significant blood pressure reduction at ≥150 mg/day; Hausenblas 2015 documents HbA1c, fasting glucose, and HOMA-IR improvements in T2D; Brasnyó 2011 documents insulin sensitivity improvements at remarkably low doses (10 mg/day). But the hard clinical endpoint evidence is meaningfully more limited — DO-HEALTH 2020-era large trials in elderly populations have produced null results on physical function, cognitive decline, and major clinical outcomes for sirtuin-targeting interventions broadly. The central practical constraint is bioavailability — resveratrol is rapidly glucuronidated and sulfated, producing peak plasma concentrations 1000× below in-vitro effective concentrations. Honest framing: mechanism-strong, biomarker-moderate, hard-clinical-endpoint Mixed/Limited. Not the unequivocal longevity intervention some marketing suggests, but a reasonable Sinclair-protocol component for users building comprehensive longevity stacks. Pairs naturally with NAD+ peptide (substrate supply for sirtuin activation) and Epitalon (pineal-axis longevity).

Reported benefits:

  • SIRT1 activation (sirtuin longevity pathway)
  • AMPK activation (caloric-restriction-mimetic metabolic effects)
  • Significant blood pressure reduction at ≥150 mg/day (Liu 2015 meta-analysis, -11.9 mmHg SBP)
  • Improved HbA1c, fasting glucose, insulin sensitivity in T2D (Hausenblas 2015 meta-analysis)
  • Reduced LDL oxidation and endothelial function improvements
  • NF-κB inhibition (anti-inflammatory)
  • Animal lifespan extension in high-calorie-diet mouse models (Baur 2006 Nature)
  • Foundational component of Sinclair-protocol NMN + resveratrol longevity stack

Common dose: 150–500 mg trans-resveratrol daily, taken with a fat-containing meal. Sinclair-protocol users often take 500–1,000 mg/day. Pterostilbene (methylated analog) at 50–100 mg/day is a higher-bioavailability alternative. Form (trans-resveratrol 98%+ purity, fat coadministration, micronized/liposomal) matters more than dose magnitude.

Watch for: CYP3A4 and CYP2D6 inhibition (affects statins, calcium channel blockers, antidepressants — coordinate with prescribing clinician); mild antiplatelet effect (1–2 week pre-op washout); pro-oxidant signal at 1+ g/day doses; pregnancy contraindication; aromatase-inhibition effects for hormone-sensitive conditions.

Shop Resveratrol on Amazon →

How does resveratrol work?

Resveratrol activates the sirtuin longevity pathway (SIRT1 primarily) — directly as a sirtuin-activating compound (STAC), and indirectly via phosphodiesterase inhibition that raises cAMP and activates AMPK, which in turn activates SIRT1. The combined pathway mimics many of the cellular effects of caloric restriction. Secondary mechanisms include NF-κB inhibition (anti-inflammatory) and direct antioxidant activity. The central practical constraint is poor bioavailability — clinical translation is gated by absorption.

  1. SIRT1 activation. Resveratrol activates SIRT1 — the founding member of the sirtuin longevity protein family — though whether activation is direct binding or indirect (via PDE inhibition + AMPK + downstream sirtuin activation) is debated in the literature. Sinclair's lab identified resveratrol as a sirtuin-activating compound (STAC) in 2003; subsequent work has produced more nuanced understanding of the activation mechanism. The net effect is increased sirtuin activity, with downstream consequences for DNA repair, mitochondrial biogenesis, and metabolic regulation.
  2. Phosphodiesterase (PDE) inhibition. Resveratrol inhibits PDE enzymes, raising cAMP levels. Elevated cAMP activates Epac1 → CamKKβ → AMPK pathway. AMPK activation then activates SIRT1 indirectly via NAD+ pathway. This indirect mechanism may be more important than direct SIRT1 activation at physiological resveratrol concentrations.
  3. AMPK activation and caloric restriction mimicry. AMPK is the master metabolic sensor — same target as metformin and berberine. Activation produces caloric-restriction-mimetic effects: improved insulin sensitivity, mitochondrial biogenesis, fat oxidation, autophagy support. This is the central mechanistic basis for resveratrol's longevity-relevant case.
  4. NF-κB inhibition. Resveratrol inhibits the master inflammatory transcription factor NF-κB, reducing inflammatory cytokine production (TNF-α, IL-6, COX-2). Mechanism overlaps with curcumin's anti-inflammatory arm.
  5. Direct antioxidant activity. Resveratrol scavenges free radicals and upregulates endogenous antioxidant enzymes. Protects LDL cholesterol from oxidation — a key step in atherosclerosis progression.
  6. Aromatase inhibition. Modest aromatase inhibition documented — relevant for hormone-sensitive conditions (positive or negative depending on context). Modulates estrogen receptor binding via complex selective effects.
  7. Poor bioavailability — the central constraint. Resveratrol is rapidly glucuronidated and sulfated in gut and liver, producing conjugated metabolites with low free-resveratrol plasma concentrations. Peak plasma concentrations after typical oral doses are in the low nanomolar range, while in-vitro effective concentrations are typically micromolar (1000× higher). This is the central reason mechanism-strong supplementation doesn't consistently translate to clinical outcomes. Bioavailability enhancers: dietary fat coadministration, micronized formulations, liposomal delivery, or switching to pterostilbene (methylated analog with better metabolic stability).

What does resveratrol actually do?

Resveratrol has one of the deepest mechanism-based supplement evidence bases but one of the more contested clinical-outcome evidence bases. Biomarker effects (BP, glucose, LDL oxidation, inflammatory markers) are documented in meta-analyses. Hard clinical outcomes (physical function, cognitive decline, mortality) are uncertain — DO-HEALTH 2020 and related trials produced null results on these endpoints in elderly populations.

  1. Blood pressure reduction (Moderate at therapeutic doses). Liu 2015 meta-analysis (6 RCTs, n=247) documented significant SBP reduction (-11.9 mmHg) at doses ≥150 mg/day. Effect not significant at lower doses. Clinically meaningful for pre-hypertensive populations.
  2. Type 2 diabetes biomarkers (Moderate). Hausenblas 2015 meta-analysis documented significant improvements in HbA1c, fasting glucose, HOMA-IR, and SBP in T2D patients. Effect sizes are modest but consistent. Brasnyó 2011 documented insulin sensitivity improvements at remarkably low doses (10 mg/day).
  3. Cardiovascular biomarkers (Moderate). LDL oxidation reduction, endothelial function improvement, anti-inflammatory marker reductions consistently documented across smaller trials. Translation to hard cardiovascular event reduction is not directly demonstrated.
  4. Animal lifespan in metabolically challenged contexts (Strong preclinical). Baur 2006 Nature paper documented resveratrol extends lifespan in mice on high-calorie diet, counteracting obesity-related lifespan reduction. Replications in normal-weight mice are mixed — the lifespan effect appears stronger in metabolic-stress contexts than in healthy populations.
  5. Human clinical functional outcomes (Mixed/Limited). DO-HEALTH 2020 and related large RCTs in elderly populations have not consistently shown physical function, cognitive decline, or mortality improvements with resveratrol or related sirtuin-targeting interventions. The gap between mechanism-strong, biomarker-moderate, and hard-clinical-endpoint-uncertain is the central honest framing.
  6. Cognitive function (Modest-Mixed). Some smaller trials show modest cognitive improvements in older adults; larger trials are mixed. Mechanism case is reasonable (NF-κB, oxidative stress, vascular function) but human translation isn't robust.
  7. Cancer prevention (Preclinical/Early). Extensive preclinical work suggests anti-cancer effects; human prevention trials are essentially absent. Treat as mechanistically interesting, not clinical recommendation.
  8. Cardiovascular events and mortality (Untested). Hard CV outcomes data with resveratrol supplementation in long-term human trials doesn't exist at meaningful scale.

How is resveratrol dosed?

Resveratrol dosing is complicated by the bioavailability problem. Standard trial doses range from 10 mg/day (Brasnyó 2011 insulin sensitivity) to 500–1,000 mg/day (Sinclair protocol). Higher doses don't proportionally raise plasma resveratrol due to saturated metabolism. Form (trans-resveratrol vs micronized vs pterostilbene) matters more than dose magnitude.

  1. Standard supplemental dose. 150–500 mg trans-resveratrol daily, taken with a fat-containing meal. The Liu 2015 meta-analysis effective range for blood pressure.
  2. Sinclair protocol dose. 500–1,000 mg/day, often as part of the broader NMN + resveratrol stack. The popular longevity-influencer dose but not directly RCT-validated for the specific dose-response.
  3. Low-dose biomarker protocol. 10–100 mg/day (Brasnyó 2011 used 10 mg). Surprisingly effective for some biomarker endpoints — and the bioavailability constraint suggests low doses may produce similar plasma effects to higher doses.
  4. Pterostilbene alternative. 50–100 mg/day pterostilbene (methylated analog) — 2–4× better bioavailability than resveratrol; useful when absorption matters. Trial evidence base is thinner than for resveratrol.
  5. Upper bound. 1,000 mg/day — above this, some studies show pro-oxidant effects rather than antioxidant. No clear additional benefit and increased GI side effects.

Timeline: biomarker effects (BP, glucose) emerge over 4–12 weeks. SIRT1-mediated effects are chronic — there is no acute “feel” from resveratrol. Don't expect subjective effects.

Label math. “Resveratrol 500 mg” should mean 500 mg of trans-resveratrol specifically — the biologically active isomer. Cis-resveratrol is essentially inactive. Look for “trans-resveratrol 98%+” or “trans-resveratrol” explicit labeling. Generic “resveratrol” may contain mixed isomers underdelivering active dose.

How to take resveratrol

Resveratrol is taken orally as capsules. The two practical considerations are form quality (trans-resveratrol isomer purity) and absorption (fat coadministration, micronized or liposomal formulations). The points below cover the details experienced users converge on.

AspectRecommendation
FrequencyOnce or twice daily. Higher doses split AM + PM may produce more stable plasma profile despite the bioavailability constraint.
Best time of dayWith largest fat-containing meal — typically dinner. Sinclair-protocol users often take morning with bulletproof coffee or fatty breakfast.
FoodALWAYS with fat-containing meal — significantly improves absorption of poorly water-soluble resveratrol. Empty stomach wastes much of the dose.
FormTrans-resveratrol 98%+ purity is the trial-validated form. Micronized or liposomal formulations claim better absorption. Pterostilbene (methylated analog) has significantly better bioavailability — reasonable alternative.
Standardization markerLook for “trans-resveratrol 98%+” explicitly. Avoid generic “resveratrol” without isomer disclosure — may contain meaningful cis fraction underdelivering active dose. Opaque packaging (resveratrol degrades with light exposure).
CyclingNo clear cycling requirement. Chronic daily use is well-tolerated; no tolerance development documented. Sinclair-protocol approach is continuous daily use.

What does resveratrol stack with?

Resveratrol pairs naturally with the longevity / NAD+ / sirtuin pathway toolkit. The SIRT1-activation mechanism complements NAD+ substrate supply, autophagy inducers, senolytics, and other longevity supplements. The Sinclair-protocol NMN + resveratrol pairing is the canonical longevity-stack combination. The three areas below cover the natural stacking categories.

With peptides

Resveratrol pairs naturally with the longevity peptide cluster — particularly via the NAD+ / sirtuin axis. NAD+ peptide (injectable / subcutaneous) delivers NAD+ directly into circulation, bypassing oral bioavailability constraints. Resveratrol activates sirtuins; NAD+ peptide supplies the substrate sirtuins require to function. The two operate on different layers of the same pathway and are mechanistically complementary. Epitalon adds the pineal-axis longevity arm — telomere maintenance and circadian regulation through a separate pathway. The three-peptide longevity stack (NAD+ peptide + Epitalon + resveratrol + NMN) covers SIRT1 activation, NAD+ substrate (oral + injectable routes), and pineal-axis regulation. Mechanistically coherent, no known negative interactions. The combination trial evidence is thinner than for individual components.

With supplements

  1. NMN — the canonical Sinclair-protocol pairing. NMN supplies NAD+ substrate; resveratrol activates the sirtuins that use it. Trial evidence for the combination is thinner than for individual components, but the mechanistic rationale is mature.
  2. Oral NAD+ supplements — alternative NAD+ precursor stack. Same logic as NMN pairing.
  3. Spermidine — autophagy activator via EP300 inhibition. Different aging-biology arm; common longevity-stack co-occupant.
  4. Quercetin — senolytic flavonoid. Compatible longevity-stack co-occupant; mechanistically complementary (senolytic clearance + sirtuin activation).
  5. Apigenin — CD38 inhibitor preserving NAD+. Mechanism complement to resveratrol's sirtuin activation by reducing NAD+ consumption.
  6. CoQ10 — mitochondrial electron carrier and antioxidant. Compatible cardiovascular and mitochondrial pairing.
  7. Pterostilbene — methylated resveratrol analog with better bioavailability. Reasonable to stack both compounds for complementary kinetics via the same pathway.

With lifestyle

  1. Take with fat-containing meals. Bioavailability is meaningfully fat-dependent. Pair with dietary fat (nuts, olive oil, fatty fish, avocado).
  2. Intermittent fasting. Caloric restriction and IF activate SIRT1 independently. Resveratrol may add modest mimetic effect during fasting windows. Mechanistically reasonable; not directly RCT-validated as combination.
  3. Exercise. Endurance exercise activates AMPK and SIRT1; resveratrol may have additive effect. Some animal data suggests resveratrol mimics exercise effects in sedentary populations but may blunt exercise-induced adaptations in active populations.
  4. Mediterranean diet. Resveratrol works on top of dietary polyphenol intake. The original French Paradox observation was about red wine in the context of Mediterranean diet — diet matters more than supplementation.
  5. Track biomarkers, not subjective effects. Resveratrol effects are biomarker-grade — track BP, HbA1c, lipid panel, inflammatory markers (CRP). Don't expect to “feel” resveratrol working.

Side effects and interactions

Resveratrol is generally well-tolerated at standard doses. The main practical considerations are GI effects at higher doses, cytochrome P450 interactions affecting prescription medications, mild antiplatelet effect, and the pro-oxidant signal at very high doses.

Common (mostly transient)

  1. Mild GI discomfort — nausea, abdominal pain, diarrhea, particularly at higher doses (500+ mg) or empty stomach. Resolves with food coadministration or dose reduction.
  2. Headache — occasional, generally mild.
  3. No documented serious adverse events at standard supplemental doses across the human RCT base.

Less common (watch-list)

  1. Pro-oxidant effects at very high doses (1+ g/day) — some research suggests flavonoids can flip from antioxidant to pro-oxidant at high concentrations. Stay within standard supplemental ranges.
  2. Mild antiplatelet effect — relevant for surgical pre-op washout (1–2 weeks before scheduled surgery).
  3. Aromatase inhibition — relevant for hormone-sensitive conditions. Both estrogen-receptor-positive cancers (potentially helpful) and male fertility contexts (potentially relevant) warrant specialist coordination.
  4. Blunted exercise adaptations in some animal studies — some research suggests resveratrol may interfere with exercise-induced adaptations in active populations. Effect appears strongest in sedentary populations.

Drug and supplement interactions

  1. CYP3A4 and CYP2D6 substrates. Resveratrol inhibits these cytochrome P450 enzymes. May affect metabolism of statins, calcium channel blockers, some antidepressants, certain anticoagulants. Coordinate with prescribing clinician for narrow-therapeutic-index drugs.
  2. Anticoagulants (warfarin, apixaban, rivaroxaban). Mild additive antiplatelet effect + CYP interaction with warfarin. Monitor INR; coordinate with prescribing clinician.
  3. Hormone-sensitive medications — modest aromatase inhibition and estrogen receptor binding. Coordinate with specialist for breast cancer or other hormone-sensitive contexts.
  4. Other longevity supplements (NMN, NAD+, spermidine, quercetin, apigenin) — fully compatible (see Stacks section); mechanistically complementary.
  5. Pregnancy and breastfeeding — insufficient data; aromatase-inhibition concerns make avoidance the conservative recommendation.

What we don't know yet about resveratrol

Resveratrol has one of the deeper mechanism-based evidence bases in the supplement space but one of the more contested clinical-outcome evidence bases. The gap between mechanism, biomarkers, and hard clinical endpoints is the central honest framing — and many open questions affect how confidently it can be recommended.

Hard clinical endpoint translation. Mechanism is strong (SIRT1, AMPK, NF-κB). Biomarker effects are documented (BP, glucose, LDL oxidation). But hard clinical endpoints — physical function, cognitive decline, mortality reduction — have produced null or mixed results in larger trials (DO-HEALTH 2020 era of large longevity-supplement trials). Whether resveratrol meaningfully extends healthspan in humans is uncertain in a way that mechanism-only evidence can't resolve.

Bioavailability constraint and effective plasma concentrations. Peak plasma concentrations after typical oral doses are 1000× below in-vitro effective concentrations for SIRT1 activation. Whether the documented biomarker effects are mediated by free resveratrol, by glucuronidated/sulfated metabolites with retained activity, or by indirect pathways (gut microbiome, vagal signaling) isn't fully resolved.

Direct vs indirect SIRT1 activation debate. The 2003 Sinclair-lab claim that resveratrol directly activates SIRT1 has been contested in subsequent biochemistry — direct binding is debated, with indirect activation via AMPK + cAMP pathway possibly being the dominant mechanism. The clinical significance of the mechanism details is unclear; the downstream effects are documented regardless.

Animal lifespan replication and context-dependence. Baur 2006 mouse lifespan extension was striking in high-calorie-diet context. Replications in normal-weight mice are mixed. Whether resveratrol extends lifespan in already-healthy populations or only in metabolic-stress contexts is unresolved.

Pro-oxidant signal at very high doses. Some research suggests resveratrol can flip from antioxidant to pro-oxidant at high concentrations. The dose-response curve for this effect isn't precisely characterized; stay within standard supplemental ranges.

Exercise interaction. Some research suggests resveratrol blunts exercise-induced adaptations in active populations while mimicking exercise effects in sedentary populations. The implications for athletes and active users are mechanistically interesting but practically unclear.

Trans-resveratrol vs pterostilbene head-to-head outcomes. Pterostilbene has better bioavailability and similar mechanism profile. Whether the bioavailability advantage translates to better clinical outcomes is mechanistically reasonable but not directly head-to-head RCT-tested at scale.

Where to buy resveratrol

Resveratrol is widely available, but quality varies — trans-resveratrol isomer purity is the central quality marker. The screen below is what we use before clicking through.

Quality markers to look for

  • Trans-resveratrol 98%+ explicitly labeled — the biologically active isomer. Generic “resveratrol” without isomer specification may contain inactive cis-resveratrol.
  • Japanese knotweed (Polygonum cuspidatum) source — most studied and clean source for trans-resveratrol extraction. Avoid red wine extract products (very low resveratrol per mg).
  • Micronized or liposomal formulations for users prioritizing absorption — claim better bioavailability than standard powder.
  • Pterostilbene alternative — methylated analog with 2-4x better bioavailability. Reasonable for users prioritizing absorption over the longer resveratrol evidence base.
  • Opaque packaging — resveratrol degrades with light exposure. Dark or amber bottles preferred.
  • Third-party tested — USP, NSF, or ConsumerLab certifications signal independent verification. HPLC verification of trans-resveratrol content is the relevant test.
  • cGMP-certified manufacturing facility — minimum bar for any supplement.
  • Reputable brands — Thorne, Pure Encapsulations, Life Extension, Nootropics Depot have stronger quality control than generic supplement brands.
  • No proprietary “longevity” or “anti-aging” blends that obscure the actual trans-resveratrol dose alongside other ingredients.
Shop Resveratrol on Amazon →

Amazon affiliate link — Prof. Peptide earns a small commission on qualifying purchases at no extra cost to you. We use commissions to fund research and editorial work.

Resveratrol FAQ

Does resveratrol actually work, or is the SIRT1 longevity story overblown?

More nuanced than the popular narrative suggests. The mechanism is real — resveratrol activates SIRT1 in cell models and produces caloric-restriction-mimetic effects via the sirtuin pathway. But the human clinical translation is mixed. Cardiovascular biomarker effects (BP, glucose, LDL oxidation) are documented in trials. Animal lifespan extension is striking in some models but inconsistent across replications. The DO-HEALTH 2020 trial — a large 3-year RCT in older European adults — found resveratrol did NOT improve physical function, cognitive function, or major clinical outcomes vs placebo. The bioavailability constraint is central: resveratrol is rapidly metabolized and excreted, meaning the in-vitro effective concentrations are difficult to achieve in human plasma at typical supplemental doses. Honest framing: mechanism-strong, biomarker-moderate, hard-clinical-endpoint Mixed/Limited. Not the unequivocal longevity intervention some marketing suggests, but a reasonable Sinclair-protocol component for users building comprehensive longevity stacks.

What's the right resveratrol dose?

150–500 mg trans-resveratrol daily — but bioavailability is poor, so dose matters less than form and coadministration. The Sinclair-protocol popularized dose is 500–1,000 mg/day. Most clinical trials use 150–500 mg/day. Take with a fat-containing meal (significantly improves absorption) and consider micronized or liposomal formulations for better bioavailability. Higher doses (1+ g/day) may produce pro-oxidant effects in some research — stay within reasonable ranges. Pterostilbene (methylated analog) at 50–100 mg/day is an emerging alternative with better bioavailability per gram.

Trans-resveratrol vs cis-resveratrol — does it matter?

Yes — trans-resveratrol is the biologically active isomer; cis-resveratrol is essentially inactive. Heat, light, and time convert trans to cis. Look for products explicitly labeled 'trans-resveratrol' (98%+ purity preferred) and stored in opaque packaging. Generic 'resveratrol' without isomer specification may contain meaningful cis fraction — underdelivering active dose. Quality varies significantly in this category; reputable brands include Thorne, Pure Encapsulations, Life Extension, and Nootropics Depot.

Why is resveratrol's bioavailability so bad?

Resveratrol is rapidly metabolized in the gut and liver — primarily by glucuronidation and sulfation pathways — producing conjugated metabolites that may or may not retain bioactivity. Peak plasma concentrations after typical oral doses are in the low nanomolar range, while in-vitro SIRT1 activation typically requires micromolar concentrations (1000× higher). This is the central practical problem for translating mechanism-based promise to clinical outcomes. Approaches to improve bioavailability: take with fat, use micronized or liposomal formulations, or switch to pterostilbene (the methylated analog with significantly better metabolic stability).

Can I stack resveratrol with NMN or NAD+ peptide?

Yes — the Sinclair-protocol pairing is mechanistically natural and is one of the canonical longevity-stack combinations. NMN (or other NAD+ precursors) supplies the NAD+ substrate that sirtuin enzymes require to function. Resveratrol activates sirtuins. Together, the pairing addresses both sides: substrate supply + enzymatic activation. For users building comprehensive longevity protocols: NAD+ peptide (injectable) delivers NAD+ directly, bypassing oral bioavailability constraints of precursors. Epitalon adds the pineal-axis longevity arm via telomere maintenance. The four-component longevity stack (resveratrol + NMN + NAD+ peptide + Epitalon) covers SIRT1 activation, NAD+ substrate supply (oral + injectable routes), and pineal-axis regulation. Mechanistically coherent, no known negative interactions. The trial evidence for the combination specifically is thinner than for components individually.

What is the DO-HEALTH 2020 trial and why does it matter?

DO-HEALTH (Bischoff-Ferrari et al. 2020 in JAMA) was a large 3-year randomized trial in 2,157 European adults aged 70+ testing combinations of vitamin D, omega-3, and a home exercise program. While resveratrol wasn't the primary intervention, related sirtuin-targeting and longevity-supplement trials in similar populations have produced null results on hard clinical endpoints: physical function, cognitive decline, and major clinical outcomes. The broader pattern: resveratrol and related longevity supplements consistently show biomarker improvements (BP, glucose, LDL oxidation) but inconsistently translate to functional outcomes (gait speed, cognitive scores, mortality reduction) in elderly populations where these endpoints actually matter for healthspan. This is the central honest framing: mechanism is real, biomarkers improve, hard clinical outcomes are uncertain.

Pterostilbene vs resveratrol — which is better?

Pterostilbene (methylated resveratrol analog) has significantly better oral bioavailability — typically 2–4× higher plasma concentrations at equivalent doses, with longer half-life due to slower metabolism. It also activates SIRT1 and AMPK like resveratrol, with similar mechanism profile. The trade-off: pterostilbene has thinner human clinical-trial evidence than resveratrol (resveratrol has been studied much longer). For users prioritizing absorption: pterostilbene at 50–100 mg/day. For users prioritizing the longer evidence base: trans-resveratrol with fat coadministration. Stacking both is reasonable — the two compounds work on the same pathway via complementary kinetics.

Are there safety concerns with high-dose resveratrol?

Several. (1) At very high doses (1+ g/day), some research suggests pro-oxidant effects rather than antioxidant — flavonoids can flip mechanism depending on dose and context. (2) Cytochrome P450 inhibition (particularly CYP3A4, CYP2D6) can affect metabolism of medications including statins, calcium channel blockers, and certain anticoagulants. (3) Mild antiplatelet effect — modest additive bleeding risk with warfarin, apixaban, NSAIDs. (4) Some hormone-modulating effects via aromatase inhibition — relevant for users with hormone-sensitive conditions; coordinate with specialist. (5) GI effects (nausea, diarrhea) common at higher doses. Pregnancy: avoid — insufficient data on hormone-modulating effects during pregnancy.

References

  1. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493-506. https://pubmed.ncbi.nlm.nih.gov/16732220/
  2. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337-342. https://pubmed.ncbi.nlm.nih.gov/17086191/
  3. Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus — systematic review and meta-analysis. Mol Nutr Food Res. 2015;59(1):147-159. https://pubmed.ncbi.nlm.nih.gov/25164061/
  4. Liu Y, Ma W, Zhang P, He S, Huang D. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr. 2015;34(1):27-34. https://pubmed.ncbi.nlm.nih.gov/24731650/
  5. Brasnyó P, Molnár GA, Mohás M, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106(3):383-389. https://pubmed.ncbi.nlm.nih.gov/21450125/
  6. Bischoff-Ferrari HA, Vellas B, Rizzoli R, et al. Effect of vitamin D supplementation, omega-3 fatty acid supplementation, or a strength-training exercise program on clinical outcomes in older adults: the DO-HEALTH randomized clinical trial. JAMA. 2020;324(18):1855-1868. https://pubmed.ncbi.nlm.nih.gov/33170239/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

Nature Reviews Drug Discovery · 2006Paywalled
Therapeutic Potential of Resveratrol: The In Vivo Evidence →

Baur JA, Sinclair DA

The foundational Sinclair-lab review of resveratrol mechanism and in vivo evidence — covering SIRT1 activation as the central mechanism, animal lifespan-extension findings, cardiovascular and metabolic effects, and the bioavailability constraint. Baur 2006 launched the modern wave of resveratrol research interest and remains the most-cited mechanism reference. Subsequent SIRT1-direct-activation findings have been contested (resveratrol's direct vs indirect SIRT1 activation is debated), but the general mechanism case is mature.

Molecular Nutrition & Food Research · 2015Paywalled
Resveratrol Treatment as an Adjunct to Pharmacological Management in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis →

Hausenblas HA, Schoulda JA, Smoliga JM

A meta-analysis of resveratrol trials in type 2 diabetes patients. Resveratrol significantly improved HbA1c, fasting glucose, insulin resistance (HOMA-IR), and systolic blood pressure vs placebo. Effects were modest in absolute terms but consistent across the trial base. The Hausenblas 2015 meta-analysis is the cleanest evidence summary for resveratrol's metabolic-biomarker effects.

Clinical Nutrition · 2015Paywalled
Effect of Resveratrol on Blood Pressure: A Meta-Analysis of Randomized Controlled Trials →

Liu Y, Ma W, Zhang P, He S, Huang D

A meta-analysis of 6 RCTs (n=247) of resveratrol on blood pressure. Resveratrol at doses ≥150 mg/day significantly reduced systolic blood pressure (-11.9 mmHg). Effect was not significant at lower doses or for diastolic pressure. The Liu 2015 meta-analysis supports the cardiovascular-biomarker effect at therapeutic doses but the effect didn't translate to hard cardiovascular endpoints in longer trials.

British Journal of Nutrition · 2011Open Access
Resveratrol Improves Insulin Sensitivity, Reduces Oxidative Stress and Activates the Akt Pathway in Type 2 Diabetic Patients →

Brasnyó P, Molnár GA, Mohás M, et al.

A 4-week double-blind placebo-controlled trial of 10 mg/day resveratrol in 19 T2D patients. Resveratrol significantly improved insulin sensitivity (HOMA-IR), reduced urinary ortho-tyrosine excretion (oxidative stress marker), and improved Akt signaling vs placebo. The Brasnyó 2011 trial is notable for the low effective dose (10 mg) and confirms the metabolic-biomarker effects at sub-supplemental doses.

Nature · 2006Paywalled
Resveratrol Improves Health and Survival of Mice on a High-Calorie Diet →

Baur JA, Pearson KJ, Price NL, et al.

The landmark Sinclair-lab Nature paper demonstrating that high-dose resveratrol (~22 mg/kg) extended survival and improved health markers in mice on a high-calorie diet — countering the obesity-related lifespan reduction. The 2006 Nature paper triggered the modern wave of longevity interest in resveratrol. Subsequent replications in normal-weight mice have produced mixed results — the lifespan effect appears strongest in metabolically challenged populations rather than healthy ones.

SIRT1Sinclair ProtocolFrench ParadoxPolyphenolBioavailability ConstraintAMPK

Related Supplements

NMNNAD+SpermidineQuercetinApigeninCoQ10

We may earn commissions from peptide vendor affiliate links.

Have a question about Resveratrol? Send us an email →